# EFNA5

## Overview
EFNA5 is a gene that encodes the protein ephrin A5, a member of the ephrin family involved in cell signaling. Ephrin A5 is a glycosylphosphatidylinositol (GPI)-anchored protein that primarily functions as a ligand for Eph receptors, which are receptor tyrosine kinases. This protein plays a crucial role in various biological processes, including axon guidance, neural development, and cell migration, by facilitating cell-cell communication at the cell membrane. Ephrin A5 is particularly significant in embryonic development, where it regulates morphogenetic processes such as optic cup formation and optic fissure closure. Additionally, ephrin A5 is involved in metabolic pathways, notably in the regulation of glucose-stimulated insulin secretion in pancreatic beta cells. The gene's expression and interaction with Eph receptors have been implicated in several pathological conditions, including cancer and neurodegenerative diseases, underscoring its potential as a biomarker and therapeutic target (Oliver2019Polycombmediated; Jain2013Pharmacological; Noh2016Proper).

## Function
Ephrin A5 (EFNA5) is a member of the ephrin family that plays a significant role in cell signaling through its interaction with Eph receptors. In healthy human cells, ephrin A5 is involved in various molecular processes, including axon guidance, neural development, and cell migration. It is primarily active at the cell membrane, facilitating cell-cell communication essential for tissue patterning and organ development.

Ephrin A5 interacts with the EphB2 receptor to activate the JNK signaling pathway, which is crucial for regulating cell proliferation and apoptosis. This signaling is particularly important during embryonic development, where it ensures the proper morphogenesis of the optic cup and closure of the optic fissure. The balance between cell proliferation and apoptosis mediated by ephrin A5 is vital for maintaining the structural integrity of the developing eye (Noh2016Proper).

In the context of glucose metabolism, ephrin A5 is expressed in pancreatic beta cells and interacts with EphA receptors. This interaction is necessary for the regulation of glucose-stimulated insulin secretion (GSIS), highlighting its role in maintaining glucose homeostasis (Jain2013Pharmacological). Ephrin A5's involvement in these processes underscores its importance in both developmental and metabolic pathways.

## Clinical Significance
Alterations in the expression of the EFNA5 gene have been implicated in several diseases, particularly in cancer and neurodegenerative disorders. In high-grade serous ovarian cancer (HGSC), EFNA5 is overexpressed and associated with poor overall survival and progression-free survival. This overexpression is linked to aggressive tumor behavior and poor clinical outcomes, suggesting that EFNA5 could serve as a biomarker for disease progression and a potential therapeutic target (Jukonen2021Aggressive).

In glioblastoma (GBM), EFNA5 acts as a tumor suppressor gene. Its expression is repressed through Polycomb-mediated histone modification, specifically H3K27 trimethylation, which is enhanced by the overexpression of Bmi1. This repression is crucial for the proliferation and invasion of glioblastoma-initiating cells, indicating that targeting the EFNA5 pathway could be a potential therapeutic strategy for GBM (Oliver2019Polycombmediated).

In amyotrophic lateral sclerosis (ALS), reduced levels of EFNA5 in the cerebrospinal fluid are associated with faster disease progression. This suggests that EFNA5 plays a protective role in maintaining neuronal integrity, and its reduction may increase motor neuron vulnerability, highlighting its potential clinical significance in ALS progression (Rué2019Reduction).

## Interactions
EFNA5, a member of the ephrin family, primarily interacts with Eph receptors, which are receptor tyrosine kinases involved in various cellular processes. EFNA5 acts as a ligand for EphA2 and EphA3 receptors, which are associated with poor prognosis in glioblastoma (GBM) and are involved in cell proliferation, invasion, and neovascularization (Oliver2019Polycombmediated). In the context of glioblastoma, EFNA5's interaction with these receptors is significant, as it is repressed by Polycomb group proteins like Bmi1, which enhances tumor growth through increased trimethylation of H3K27 (Oliver2019Polycombmediated).

In addition to its role in glioblastoma, EFNA5 is part of a broader network of interactions within the EFNA family, which includes interactions with proteins such as DEPTOR, RRAGB, RPTOR, RPS6KB1, RHEB, NGEF, LAMTOR5, and LAMTOR1. These interactions are implicated in several tumor-related pathways, including PI3K-Akt, mTOR, MAPK, and Ras signaling pathways (Jiao2022Expression). However, specific details about the physical interactions of EFNA5 with other proteins or nucleic acids are not extensively detailed in the available literature.


## References


[1. (Oliver2019Polycombmediated) Thomas Oliver Millner, Barbara Ricci, Xinyu Zhang, Nicola Pomella, and Silvia Marino. Polycomb-mediated repression of ephrina5 promotes growth and invasion of glioblastoma. Neuro-Oncology, 21(Supplement_4):iv1–iv2, October 2019. URL: http://dx.doi.org/10.1093/neuonc/noz167.004, doi:10.1093/neuonc/noz167.004. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/neuonc/noz167.004)

[2. (Noh2016Proper) Hyuna Noh, Haeryung Lee, Eunjeong Park, and Soochul Park. Proper closure of the optic fissure requires ephrin a5-ephb2-jnk signaling. Development, 143(3):461–472, February 2016. URL: http://dx.doi.org/10.1242/dev.129478, doi:10.1242/dev.129478. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.129478)

[3. (Rué2019Reduction) Laura Rué, Patrick Oeckl, Mieke Timmers, Annette Lenaerts, Jasmijn van der Vos, Silke Smolders, Lindsay Poppe, Antina de Boer, Ludo Van Den Bosch, Philip Van Damme, Jochen H. Weishaupt, Albert C. Ludolph, Markus Otto, Wim Robberecht, and Robin Lemmens. Reduction of ephrin-a5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, July 2019. URL: http://dx.doi.org/10.1186/s40478-019-0759-6, doi:10.1186/s40478-019-0759-6. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40478-019-0759-6)

[4. (Jain2013Pharmacological) R. Jain, D. Jain, Q. Liu, B. Bartosinska, J. Wang, D. Schumann, S. G. Kauschke, P. Eickelmann, L. Piemonti, N. S. Gray, and E. Lammert. Pharmacological inhibition of eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia, 56(6):1350–1355, March 2013. URL: http://dx.doi.org/10.1007/s00125-013-2877-1, doi:10.1007/s00125-013-2877-1. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-013-2877-1)

[5. (Jukonen2021Aggressive) Joonas Jukonen, Lidia Moyano-Galceran, Katrin Höpfner, Elina A. Pietilä, Laura Lehtinen, Kaisa Huhtinen, Erika Gucciardo, Johanna Hynninen, Sakari Hietanen, Seija Grénman, Päivi M. Ojala, Olli Carpén, and Kaisa Lehti. Aggressive and recurrent ovarian cancers upregulate ephrina5, a non-canonical effector of epha2 signaling duality. Scientific Reports, April 2021. URL: http://dx.doi.org/10.1038/s41598-021-88382-6, doi:10.1038/s41598-021-88382-6. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-021-88382-6)

[6. (Jiao2022Expression) Zonglin Jiao, Xiao Feng, Yuqing Cui, Lei Wang, Junqing Gan, Yanbin Zhao, and Qingwei Meng. Expression characteristic, immune signature, and prognosis value of efna family identified by multi-omics integrative analysis in pan-cancer. BMC Cancer, August 2022. URL: http://dx.doi.org/10.1186/s12885-022-09951-0, doi:10.1186/s12885-022-09951-0. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-022-09951-0)